JPMorgan Initiates Hims & Hers (HIMS) Coverage With Cautious Stance on GLP-1 Transition

Key Takeaways

• JPMorgan initiated coverage on HIMS with a Neutral stance and $32 price objective, representing roughly 16% potential appreciation from present levels
• Analysts express concern over the telehealth company’s transition from compounded GLP-1 medications to FDA-sanctioned branded alternatives such as Wegovy
• Through its collaboration with Novo Nordisk, the company processed over 125,000 Wegovy orders during the initial six-week period
• Second-quarter revenues reached $753.21 million, reflecting a 38.2% annual increase, though the firm significantly underperformed earnings expectations with a $0.37 per share loss versus the anticipated $0.05 loss
• Additional headwinds include an FTC complaint alongside an ongoing securities class action litigation

HIMS began Friday’s session at $27.52, considerably beneath its $65.30 yearly peak. The new $32 objective from JPMorgan signals measured optimism rather than bullish enthusiasm. Shares declined roughly 1% during trading.

Hims & Hers Health, Inc., HIMS

Bryan Smilek, analyst at JPMorgan, launched coverage with a Neutral designation, acknowledging the firm’s impressive expansion while highlighting substantial execution challenges linked to its GLP-1 product transformation.

The telehealth platform announced during March its decision to cease promoting compounded GLP-1 treatments and transition exclusively toward FDA-sanctioned branded pharmaceuticals. This strategic shift presents notable challenges. Revenue from compounded products is declining while branded product volume continues building.

Smilek forecasts 2026 GLP-1 revenues reaching $1.1 billion, marking a 46% annual climb, propelled by the Novo Nordisk collaboration. His analysis suggests the Wegovy agreement should adequately compensate for revenue losses from discontinued compounded offerings.

The Novo collaboration started strongly. The company processed more than 125,000 Wegovy orders during merely the opening six-week window.

JPMorgan anticipates substantial growth potential within the GLP-1 sector. Their projections indicate U.S. cash-paying GLP-1 consumers could expand from approximately 2.8 million currently to over 8 million by decade’s end.

Management has established ambitious 2030 objectives exceeding $6.5 billion in revenue and surpassing $1.3 billion in adjusted EBITDA, fueled by global expansion initiatives and emerging categories including peptide therapies.

Financial Performance Overview

The most recent quarterly report presented contrasting signals. Revenue totaling $753.21 million exceeded the $698.90 million consensus and demonstrated 38.2% year-over-year expansion.

However, profitability metrics proved troublesome. The organization recorded a $0.37 per share deficit, substantially worse than the projected $0.05 loss. This disappointing variance concerned market participants.

Shares declined 7.7% post-announcement, per Zacks data, demonstrating HIMS’s vulnerability to earnings performance concerns.

Regulatory and Legal Complications Mount

Beyond disappointing earnings, HIMS confronts two significant legal challenges. An FTC complaint alleges misleading and illegal privacy violations. Additionally, a securities class action encompasses shareholders from August 2025 through July 2026, with November 2, 2026 established as the lead-plaintiff deadline.

While neither matter has reached court resolution, both contribute to investor uncertainty.

Overall Wall Street sentiment remains at a consensus Hold rating. Among 16 analysts monitored by MarketBeat, 12 recommend Hold, three suggest Buy, and one advises Sell. The consensus price objective stands at $32.43.

JPMorgan’s Smilek indicated he requires evidence that the branded GLP-1 transformation succeeds, emerging specialty areas demonstrate sustainable growth, and profit margins improve before adopting a more optimistic outlook.

Company insiders have reduced positions recently. During the previous 90-day period, insiders liquidated 190,227 shares valued above $6.1 million.